Physician profile
Jun Gong
NPI 1538426101
$117,341.64
in general payments reported to CMS, 2019-2025
33 companies · $53K in 2025
The $53K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,557 · 2021: $9,238 · 2022: $16K · 2023: $10K · 2024: $9,364 · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $62K · Honoraria: $4,424 · Travel and Lodging: $3,628 · Food and Beverage: $3,000 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $61,550.50 |
| Honoraria | $4,423.50 |
| Travel and Lodging | $3,628.07 |
| Food and Beverage | $2,999.64 |
| Education | $217.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $24,323.83 | 2025 | Tevimbra |
| Astrazeneca Pharmaceuticals LP | $11,990.28 | 2025 | Imfinzi |
| Seagen INC. | $10,316.09 | 2022-2023 | Padcev, Tukysa |
| Incyte Corporation | $8,051.99 | 2022-2025 | Zynyz, Zynyz |
| Pfizer INC. | $7,129.61 | 2024-2025 | |
| Astellas Pharma US INC | $6,608.71 | 2019 | |
| Array Biopharma INC | $6,474.87 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| F. Hoffmann-La Roche Ag | $6,065.71 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,943.33 | 2021-2025 | |
| Eisai INC. | $4,154.50 | 2020-2025 | |
| Emd Serono, INC. | $4,140.00 | 2021 | |
| Exelixis INC. | $3,960.00 | 2019-2022 | |
| Myovant Sciences INC. | $3,840.00 | 2022 | |
| Beigene USA, INC. | $2,434.32 | 2025 | Tevimbra |
| Taiho Oncology, INC. | $2,114.00 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,965.73 | 2023-2025 | Tecentriq |
| Amgen INC. | $1,785.35 | 2019 | |
| Aveo Pharmaceuticals, INC. | $1,710.06 | 2021-2023 | Fotivda |
| Merck Sharp & Dohme LLC | $1,272.24 | 2019 | |
| Janssen Biotech, INC. | $1,000.00 | 2021 | |
| Hoffmann-La Roche Limited | $848.66 | 2020 | |
| Daiichi Sankyo INC. | $412.66 | 2022-2025 | Enhertu |
| G1 Therapeutics, INC. | $182.41 | 2022 | |
| Intera Oncology, INC | $168.15 | 2023 | Intera 3000 Implantable Pump |
| Janssen Scientific Affairs, LLC | $155.31 | 2023-2024 | Erleada, Akeega |
| Galvanize Therapeutics, INC | $103.53 | 2024 | Aliya System |
| Glaxosmithkline, LLC. | $67.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $46.87 | 2020 | |
| Abbvie INC. | $28.87 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $28.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.42 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Gong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.